تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
1.02 US$
+0.0219 US$ · +2.19%
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
الإغلاق السابق
1.02 US$
+0.0219 US$ · +2.19%
قبل افتتاح السوق
1.00 US$
−0.02 US$ · -1.96%
8 أكتوبر، 8:44 ص ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
نطاق اليوم
السعر الحالي 1.02 US$
نطاق 52 أسبوعًا
السعر الحالي 1.02 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
33
مرتفع السعر
المشاعر
67
صعودي
المخاطر
61
مخاطر مرتفعة
الزخم
34
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
نطاق اليوم
السعر الحالي 1.02 US$
نطاق 52 أسبوعًا
السعر الحالي 1.02 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
4.67 US$
ارتفاع محتمل بنسبة 357.84%سجل الأسعار غير متاح
عالي: 6.00 US$متوسط: 4.67 US$قليل: 4.00 US$صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI10.02 مليون0.00%2.3 ترليون USD0.03%381.03 US$-0.40%
State Street SPDR S&P Biotech ETFXBI5.03 مليون0.05%10.08 مليار USD0.35%150.23 US$-0.44%
Vanguard Extended Market ETFVXF4.35 مليون0.00%95.4 مليار USD0.05%233.49 US$-1.56%
iShares Russell 2000 ETFIWM3.5 مليون0.00%78.56 مليار USD0.19%277.7 US$-1.29%
Vanguard Russell 2000 ETFVTWO1.8 مليون0.01%18 مليار USD0.06%112.21 US$-1.26%
Fidelity Enhanced Small Cap ETFFESM1.62 مليون0.02%6.41 مليار USD0.28%45.22 US$-1.14%
Vanguard Health Care ETFVHT695.68 ألف0.00%22 مليار USD0.09%315.31 US$+0.78%
iShares Micro-Cap ETFIWC409.93 ألف0.03%1.33 مليار USD0.60%183.36 US$-1.09%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
